Jobs
-
Takeda Pharmaceutical has announced that it will lay off approximately 2,800 employees — 2,100 in Europe and 700 in the US — as it realigns to accommodate its 2011 acquisition of Nycomed. Nycomed’s products include… Read more . . .
-
Manufacturer Church & Dwight UK has informed the Medicines and Healthcare products Regulatory Agency (MHRA) of possible bacterial contamination of its Sterimar Isotonic 100ml saline nasal spray, which is available over the counter in the… Read more . . .
-
After the rejection of its last offer in December, Valeant Pharmaceuticals says that it has increased its offer for ISTA to $7.50 per share from $6.50 and adds that it has informed ISTA that the… Read more . . .
-
MAP Pharmaceuticals has appointed W. James O’Shea, a former President and COO of Sepracor, to its board of directors. During eight years at Sepracor, O’Shea held a number of positions in operations and commercialization and… Read more . . .
-
A new report available from BCC Research projects a compound annual growth rate (CAGR) of 14.3% for the respiratory drug delivery technologies market, meaning that the global market would approximately double to $44 billion by… Read more . . .
-
Applications due by January 31, 2012. Details of the award and submission information are avaiable on this document. The application form is available here. Applicants must work in academia or small and medium enterprises (SMEs)… Read more . . .
-
According to an interim management statement released by Vectura, the company anticipates a cut R&D expenditures by £1m for the fiscal year ending March 31 2012 and expects additional cuts for FY2013. The company said,… Read more . . .
-
Fleming Pharmaceuticals says that it sold the rights to its Ocean brand saline nasal products, along with three other products, to Valeant, which will distribute the product through Valeant Pharmaceuticals North America LLC. Ocean nasal… Read more . . .
-
California pharmaceutical company Inverseon has announced that it will redirect its development program for INV102, an inverse beta agonist, to focus on smoking cessation and COPD rather than asthma, although it is continuing to seek… Read more . . .
-
According to an article published online in the American Thoracic Society’s American Journal of Respiratory and Critical Care Medicine, only about a third of asthma patients not using an inhaled corticosteroid (ICS) and 17% of… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland